Reminyl Gets New Name – Razadyne – Ahead Of ER Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.
You may also be interested in...
Johnson & Johnson Creates Primary Care Unit From Ortho-McNeil And Janssen
PriCara will market primary care-focused products including Levaquin, Aciphex and Duragesic.
Johnson & Johnson Creates Primary Care Unit From Ortho-McNeil And Janssen
PriCara will market primary care-focused products including Levaquin, Aciphex and Duragesic.
Razadyne Paragraph IV Certification
The first ANDA with a Paragraph IV certification for Johnson & Johnson's Alzheimer's product Razadyne (galantamine, formerly Reminyl) was filed Feb. 28, according to FDA's May 3 updated list of filings